Vieira Roberto Wandenkolk sold $674K of CORT
Vieira Roberto Wandenkolk (President, Oncology) sold 8,333 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $80.89 ($80.73–$81.52, $0.67M total) across 2 trades on 2026-11-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest in size relative to the insider's remaining stake and may not materially affect price.
Market read
A routine insider sale with limited market impact; traders may note the transaction but unlikely to act on it.
What to watch
Upcoming clinical trial data or partnership announcements could offset the negative perception of the insider sale.
Background
Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates a pre‑arranged sale schedule.
Ticker impact
President of Oncology sold 8,333 shares for $674K via a 10b5‑1 plan, reducing holdings to 3,946 shares.
likely modest pressure as the market prices in the insider sell
The sale size is relatively small for a mid‑cap biotech and was pre‑arranged, limiting the strength of the signal.
Market effects
Minimal impact on the broader biotech sector; insider sales are routine and unlikely to shift sector sentiment.
No regional effect; the filing is US‑focused.
Low global relevance; limited to investors tracking Corcept Therapeutics.
Counterpoint
The sale could be purely liquidity‑driven under a 10b5‑1 plan, not reflecting any negative outlook on the company.
Key entities
- personVieira Roberto Wandenkolk
President, Oncology at Corcept Therapeutics
- companyCorcept Therapeutics Inc
Biopharmaceutical company focused on cortisol‑related therapies


